🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11274342

Systems and methods for sequencing T cell receptors and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11267893

Anti-IL36R antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11261248

Restricted immunoglobulin heavy chain mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11253572

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254752

Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibo

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11248044

Methods for altering body composition by administering a GDF8 inhibitor and an Activin A i

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11241498

Room temperature stable lyophilized protein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11241499

Human serum albumin in formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11214621

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagon

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208458

Compositions and methods for internalizing enzymes

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11191844

Multispecific antigen-binding molecules and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186625

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180540

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11178860

Humanized C5 animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174305

Human antibodies to Fel d1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174283

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11167004

Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168111

Readily isolated bispecific antibodies with native immunoglobulin format

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155598

GPR156 variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155633

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155621

Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11142578

Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of us

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11130999

Cas-ready mouse embryonic stem cells and mice and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129903

Multispecific antigen-binding molecules and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted